{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T09:32:56Z","timestamp":1750930376609,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s10875-024-01698-6","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T07:01:51Z","timestamp":1712559711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of Progressive Multifocal Leukoencephalopathy with IL-2 and Mirtazapine"],"prefix":"10.1007","volume":"44","author":[{"given":"Lorne","family":"Schweitzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sapha","family":"Barkati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Laneuville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1347-7767","authenticated-orcid":false,"given":"Donald C.","family":"Vinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"issue":"1","key":"1698_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","volume":"17","author":"I Cortese","year":"2021","unstructured":"Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021;17(1):37\u201351.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"1698_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40261-016-0433-8","volume":"36","author":"Y Jamilloux","year":"2016","unstructured":"Jamilloux Y, Kerever S, Ferry T, Broussolle C, Honnorat J, S\u00e8ve P. Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine. Clin Drug Investig. 2016;36(10):783\u20139.","journal-title":"Clin Drug Investig"},{"issue":"17","key":"1698_CR3","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","volume":"380","author":"I Cortese","year":"2019","unstructured":"Cortese I, Muranski P, Enose-Akahata Y, Ha S-K, Smith B, Monaco M, et al. Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. New Engl J Med. 2019;380(17):1597\u2013605.","journal-title":"New Engl J Med"},{"issue":"8","key":"1698_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S1474-4422(21)00174-5","volume":"20","author":"I Cortese","year":"2021","unstructured":"Cortese I, Beck ES, Al-Louzi O, Ohayon J, Andrada F, Osuorah I, et al. BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study. Lancet Neurol. 2021;20(8):639\u201352.","journal-title":"Lancet Neurol"},{"key":"1698_CR5","doi-asserted-by":"publisher","first-page":"204062072312017","DOI":"10.1177\/20406207231201721","volume":"14","author":"FW Hoff","year":"2023","unstructured":"Hoff FW, Rolwes J, Hardeman PA, Perkins M, Major EO, Douek D, et al. Long-term outcome of progressive multifocal leukoencephalopathy with recombinant interleukin-2 treatment and an associated increase in the number of HPyV-2-specific T-cells: a case report. Ther Adv Hematol. 2023;14:20406207231201720.","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"1698_CR6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/ana.26307","volume":"91","author":"R Lajaunie","year":"2022","unstructured":"Lajaunie R, Mainardi I, Gasnault J, Rousseau V, Tarantino AG, Sommet A, et al. Outcome of Progressive Multifocal Leukoencephalopathy Treated by Interleukin-7. Ann Neurol. 2022;91(4):496\u2013505.","journal-title":"Ann Neurol"},{"issue":"2","key":"1698_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.26512","volume":"93","author":"X Boumaza","year":"2023","unstructured":"Boumaza X, Bonneau B, Roos-Weil D, Pinnetti C, Rauer S, Nitsch L, Immunotherapy for PML Study Group, et al. Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors. Ann Neurol. 2023;93(2):257\u201370.","journal-title":"Ann Neurol."},{"key":"1698_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cytogfr.2022.06.003","volume":"67","author":"P Zhou","year":"2022","unstructured":"Zhou P. Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity. Cytokine Growth Factor Rev. 2022;67:80\u20138.","journal-title":"Cytokine Growth Factor Rev"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01698-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-024-01698-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01698-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T10:11:30Z","timestamp":1719223890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-024-01698-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1698"],"URL":"https:\/\/doi.org\/10.1007\/s10875-024-01698-6","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"type":"print","value":"0271-9142"},{"type":"electronic","value":"1573-2592"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"13 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Research Ethics Board of the Research Institute \u2013 McGill University Health Centre has approved this research (No.\u00a02021\u20136624).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors confirm that a relevant local consent has been signed by the patient and\/or the legally authorized representative.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors confirm that a relevant local consent has been signed by the patient and\/or the legally authorized representative.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"D.C. Vinh has received research support, unrestricted educational grants, consultancy fees, and speaker honoraria from CSL Behring; has received consultancy fees from AstraZeneca, Moderna, and Takeda; and has undertaken clinical trials for Cidara Therapeutics and Moderna. The remaining authors declare no competing financial interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}}],"article-number":"97"}}